313 related articles for article (PubMed ID: 26150380)
1. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
2. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
Noujaim J; Thway K; Jones RL; Miah A; Khabra K; Langer R; Kasper B; Judson I; Benson C; Kollàr A
Anticancer Res; 2015 Nov; 35(11):6213-7. PubMed ID: 26504053
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Synovial sarcoma relapses in children and adolescents: prognostic factors, treatment, and outcome.
Soole F; Maupain C; Defachelles AS; Taque S; Minard-Colin V; Bergeron C; De Rycke Y; Orbach D
Pediatr Blood Cancer; 2014 Aug; 61(8):1387-93. PubMed ID: 24664883
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
7. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC; Rey A; Bouvet N; Ellershaw C; Flamant F; Habrand JL; Marsden HB; Martelli H; Sanchez de Toledo J; Spicer RD; Spooner D; Terrier-Lacombe MJ; van Unnik A; Oberlin O
J Clin Oncol; 2005 Apr; 23(12):2618-28. PubMed ID: 15728225
[TBL] [Abstract][Full Text] [Related]
8. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
11. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
13. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
14. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
[TBL] [Abstract][Full Text] [Related]
15. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
16. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
[TBL] [Abstract][Full Text] [Related]
17. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
[TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Faure-Conter C; Orbach D; Cropet C; Baranzelli MC; Martelli H; Thebaud E; Vérité C; Rome A; Fasola S; Corradini N; Rocourt N; Frappaz D; Kalfa N; Patte C
Pediatr Blood Cancer; 2014 Feb; 61(2):253-9. PubMed ID: 23940114
[TBL] [Abstract][Full Text] [Related]
20. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
